Clinical Trials Browser

Completed × Lethal Congenital Contracture Syndrome 2 × Clear all

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Phase 2 Completed

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT00734305 2016-09-01

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Phase 1 Completed

44 enrolled 12 charts

Lethal Congenital Contracture Syndrome 2, Neoplasms

NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

162 enrolled 11 charts

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00740532 2010-09-02

Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients

Lethal Congenital Contracture Syndrome 2, Breast Neoplasms

NCT00730470 2010-07-29

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Phase 1 Completed

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2